Delivery Order SPE2DR25D1109-SPE2DR26FFK3E
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for MD-GASTROVIEW 66%-10% Solution 30ML, a diagnostic contrast media product, with a ceiling value of $1,067.76. This firm fixed price delivery order, which carries an ultimate completion date of August 12, 2025, was competitively awarded with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for pharmaceutical supplies on October 27, 2025, with a ceiling value of $2,341.23. The contract covers the supply of Gadavist 7.5 mmol/7.5 ml vials, a gadolinium-based contrast agent used in medical imaging procedures. This is a firm fixed price delivery order with an ultimate completion date of October 28, 2025, and represents performance at the contractor's Corporate Office location in Conshohocken,...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order valued at $1,381.44 to AmerSourceBergen Drug Corp on January 8, 2026, with an ultimate completion date of January 9, 2026. This competitively awarded, non-set-aside contract employs firm fixed-price pricing and represents a task order under AmerSourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The prime contractor, headquartered in Conshohocken, Pennsylvania, is a subsidiary of...
- The Defense Logistics Agency awarded a delivery order valued at $2,946.42 to AmerisourceBergen Drug Corp for the supply of Omnipaque 350 mg/ml Pluspak 500ml, a contrast imaging agent used in diagnostic medical procedures. This non-set-aside, competitively awarded contract carries a firm fixed price structure with an ultimate completion date of December 5, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor and will fulfill performance at its...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $1,140.48 to supply Omnipaque 350 mg/ml Pluspak 500ml, a contrast medium used in medical imaging procedures. The award, issued on January 2, 2026, represents a firm fixed price delivery order with an ultimate completion date of January 5, 2026. This non-set-aside contract was competitively awarded and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 5, 2025, for the supply of Gadavist 10 mmol/10 mL vials with a ceiling value of $7,098.02. This is a firm fixed-price delivery order with an ultimate completion date of November 6, 2025, and represents a non-set-aside competitive award. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is a child contract issued under...
- This delivery order, valued at $2,119.26, was awarded to AmerSourceBergen Drug Corp on January 8, 2026, by the Defense Logistics Agency (DLA) under a competitive, non-set-aside procurement. The award represents a task order issued against AmerSourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop Support Medical, a single-award IDC valued at up to $999,999,999.00 and extending through December 31, 2031. This contract vehicle provides comprehensive...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,352.64 for Omnipaque 350 mg/ml Pluspak 500ml, a contrast agent used in diagnostic imaging procedures. The contract is a firm fixed price delivery order with an ultimate completion date of August 25, 2025, and represents a non-set-aside competitive award. Performance will be executed from the awardee's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency Medical Supply Chain awarded a $27,807 delivery order to AmerSourceBergen Drug Corp on January 8, 2026, with completion expected by January 9, 2026. This firm fixed-price, non-set-aside contract represents a task order under AmerSourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at up to $999,999,999 through December 2026. AmerSourceBergen, operating as a division of parent company Cencora, Inc., is a major...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,304.18 to AmerisourceBergen Drug Corp for Gadavist 10 mmol/10 mL vials. This is a firm fixed price, competitively awarded contract with no set-aside designation, due for completion on September 11, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The delivery order falls under the company's existing indefinite delivery contract (IDC) with DLA Troop...
- SPE2DR25D1109Indefinite Delivery Contract
- SPE2DR25D1109-SPE2DR26FFK3EDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,110.13 to AmerSourceBergen Drug Corp for MD-Gastroview 66%-10% Solution 30ML, a diagnostic contrast agent used in gastrointestinal imaging procedures. The contract, executed on January 8, 2026, with an ultimate completion date of January 9, 2026, utilizes firm fixed pricing with no set-aside designation, indicating competitive award to a qualified vendor. AmerSourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is the performing location for this delivery order. This delivery order is issued under AmerSourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. This master contract vehicle enables the company to supply a comprehensive range of pharmaceutical products and medical supplies globally to support military healthcare programs, including specialty medications, generic drugs, vaccines, and medical supplies across multiple therapeutic domains. The parent organization, Cencora, Inc., which operates under the AmerSourceBergen brand, holds an even larger IDC with DLA valued at up to $999,999,999.00 through December 31, 2031, reflecting the company's critical role in the federal pharmaceutical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 1/7/26 |